Together with additional intriguing evidence that c-Abl inhibition may exert disease-modifying effects on PD by playing a protective role against the degeneration of nigral dopaminergic cells (Ko et al., 2010; Imam et al., 2011, 2013; Hebron et al., 2013a,b), we suggest that c-Abl inhibitors may serve as an alternative agent for attenuating motor symptoms and disease progression in patients with PD. The gene discussed is ABL1; the disease is Parkinson disease.